FKBP5 polymorphisms and antidepressant response in geriatric depression

Authors

  • Jane E. Sarginson,

    1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
    Search for more papers by this author
  • Laura C. Lazzeroni,

    1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
    Search for more papers by this author
  • Heather S. Ryan,

    1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
    Search for more papers by this author
  • Alan F. Schatzberg,

    1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
    Search for more papers by this author
  • Greer M. Murphy Jr.

    Corresponding author
    1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California
    • Department of Psychiatry and Behavioral Sciences, Neuroscience Research Laboratories, Stanford University School of Medicine, Medical School Lab Surge Building, 1201 Welch Road, Stanford, CA 94305-5485.
    Search for more papers by this author

  • How to Cite this Article: Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GMJr. 2009. FKBP5 Polymorphisms and Antidepressant Response in Geriatric Depression. Am J Med Genet Part B 153B:554–560.

Abstract

Genetic variation at the FKBP5 locus has been reported to affect clinical outcomes in patients treated with antidepressant medications in several studies. However, other reports have not confirmed this association. FKBP5 may regulate the sensitivity of the hypothalamic–pituitary–adrenal axis. We tested two FKBP5 single nucleotide polymorphisms (rs1360780 and rs3800373) in a sample of 246 geriatric patients treated for 8 weeks in a double-blind randomized comparison trial of paroxetine and mirtazapine. These two polymorphisms had previously been reported to predict efficacy in depressed patients treated with selective serotonin reuptake inhibitors such as paroxetine, and those treated with mirtazapine, an agent with both serotonergic and noradrenergic actions. However, we found no significant associations between these FKBP5 genetic variants and clinical outcomes. Neither mean Hamilton Depression Rating Scale scores nor time to remission or response were predicted by FKBP5 genetic variation. These results suggest that FKBP5 is unlikely to play a major role in determining antidepressant treatment outcomes in geriatric patients. © 2009 Wiley-Liss, Inc.

Ancillary